Boston Scientific Co. (NYSE:BSX) EVP Wendy Carruthers Sells 6,983 Shares

Boston Scientific Co. (NYSE:BSX) EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.86, for a total value of $585,594.38. Following the transaction, the executive vice president now owns 34,748 shares in the company, valued at $2,913,967.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Wendy Carruthers also recently made the following trade(s):

• On Tuesday, September 3rd, Wendy Carruthers sold 6,983 shares of Boston Scientific stock. The stock was sold at an average price of $81.70, for a total transaction of $570,511.10.
• On Thursday, August 1st, Wendy Carruthers sold 6,983 shares of Boston Scientific stock. The shares were sold at an average price of $74.12, for a total transaction of $517,579.96.

Boston Scientific Price Performance

NYSE BSX traded up $0.33 on Wednesday, reaching $84.47. 4,518,125 shares of the stock traded hands, compared to its average volume of 5,994,644. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $84.89. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44. The firm’s fifty day simple moving average is $79.55 and its 200 day simple moving average is $75.56. The company has a market cap of $123.93 billion, a price-to-earnings ratio of 70.66, a P/E/G ratio of 2.78 and a beta of 0.79.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The firm had revenue of $4.12 billion for the quarter, compared to analyst estimates of $4.02 billion. During the same period in the previous year, the company earned $0.53 earnings per share. Boston Scientific’s revenue was up 14.5% compared to the same quarter last year. As a group, research analysts predict that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on BSX. Truist Financial lifted their target price on Boston Scientific from $86.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. TD Cowen boosted their price objective on Boston Scientific from $77.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Morgan Stanley increased their target price on Boston Scientific from $79.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, July 15th. Robert W. Baird boosted their price target on shares of Boston Scientific from $90.00 to $91.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $85.00 price objective on shares of Boston Scientific in a report on Thursday, July 25th. Three research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $87.10.

Institutional Trading of Boston Scientific

A number of large investors have recently added to or reduced their stakes in the business. Eagle Bay Advisors LLC boosted its stake in shares of Boston Scientific by 542.1% during the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 309 shares in the last quarter. First Foundation Advisors acquired a new position in shares of Boston Scientific in the 1st quarter valued at $25,000. Triad Wealth Partners LLC purchased a new position in Boston Scientific in the 2nd quarter worth about $26,000. Andra AP fonden acquired a new stake in Boston Scientific during the 2nd quarter worth about $29,000. Finally, RiverPark Advisors LLC purchased a new stake in Boston Scientific during the first quarter valued at about $30,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.